Insights into drug discovery from natural medicines using reverse pharmacokinetics

Trends in Pharmacological Sciences

Volumn 35, Issue 4, 2014, Pages 168-177

  Hao, Haiping ^a   Zheng, Xiao ^a   Wang, Guangji ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

gut microbiota; multiple component and multiple target drugs; remote target; target identification; translational medicine

Indexed keywords

NATURAL PRODUCT;

CHEMICAL COMPOSITION; DRUG FORMULATION; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG RESEARCH; DRUG SCREENING; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; INTESTINE FLORA; MEDIATOR; METABOLOME; METABOLOMICS; NATURAL MEDICINE; NONHUMAN; PHARMACOLOGICAL PROCEDURES; PRIORITY JOURNAL; REVERSE PHARMACOKINETICS; REVIEW; SOCIAL MEDICINE; STRUCTURE ACTIVITY RELATION; TRANSLATIONAL RESEARCH;

GUT MICROBIOTA; MULTIPLE-COMPONENT AND MULTIPLE-TARGET DRUGS; REMOTE TARGET; TARGET IDENTIFICATION; TRANSLATIONAL MEDICINE;

BIOLOGICAL PRODUCTS; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; HUMANS;

EID: 84898809667     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2014.02.001     Document Type: Review

References (86)

1. P.J. Hajduk, and J. Greer A decade of fragment-based drug design: strategic advances and lessons learned Nat. Rev. Drug Discov. 6 2007 211 219
2. J.W. Li, and J.C. Vederas Drug discovery and natural products: end of an era or an endless frontier? Science 325 2009 161 165
3. A.L. Harvey Natural products in drug discovery Drug Discov. Today 13 2008 894 901
4. D.J. Newman Natural products as leads to potential drugs: an old process or the new hope for drug discovery? J. Med. Chem. 51 2008 2589 2599
5. F.E. Koehn, and G.T. Carter The evolving role of natural products in drug discovery Nat. Rev. Drug Discov. 4 2005 206 220
6. B. Patwardhan, and R.A. Mashelkar Traditional medicine-inspired approaches to drug discovery: can Ayurveda show the way forward? Drug Discov. Today 14 2009 804 811
7. T.P. Fan et al. Angiogenesis: from plants to blood vessels Trends Pharmacol. Sci. 27 2006 297 309
8. D.X. Kong et al. Where is the hope for drug discovery? Let history tell the future Drug Discov. Today 14 2009 115 119
9. T.W. Corson, and C.M. Crews Molecular understanding and modern application of traditional medicines: triumphs and trials Cell 130 2007 769 774
10. B.M. Schmidt et al. Revisiting the ancient concept of botanical therapeutics Nat. Chem. Biol. 3 2007 360 366
11. B.B. Aggarwal, and B. Sung Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets Trends Pharmacol. Sci. 30 2009 85 94
12. Q.R. Jones et al. Target-based selection of flavonoids for neurodegenerative disorders Trends Pharmacol. Sci. 33 2012 602 610
13. A.N. Begum et al. Curcumin structure-function, bioavailability, and efficacy in models of neuroinflammation and Alzheimer's disease J. Pharmacol. Exp. Ther. 326 2008 196 208
14. L. Shen, and H.F. Ji The pharmacology of curcumin: is it the degradation products? Trends Mol. Med. 18 2012 138 144
15. T. Morimoto et al. The dietary compound curcumin inhibits p300 histone acetyltransferase activity and prevents heart failure in rats J. Clin. Invest. 118 2008 868 878
16. A.R. Neves et al. Resveratrol in medicinal chemistry: a critical review of its pharmacokinetics, drug-delivery, and membrane interactions Curr. Med. Chem. 19 2012 1663 1681
17. S.J. Park et al. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases Cell 148 2012 421 433
18. L.T. Ngo et al. 21st century natural product research and drug development and traditional medicines Nat. Prod. Rep. 30 2013 584 592
19. J. Zhang et al. Pharmacokinetics-pharmacology disconnection of herbal medicines and its potential solutions with cellular pharmacokinetic- pharmacodynamic strategy Curr. Drug Metab. 13 2012 558 576
20. C. Mancuso, and E. Barone Curcumin in clinical practice: myth or reality? Trends Pharmacol. Sci. 30 2009 333 334
21. P. Anand et al. Bioavailability of curcumin: problems and promises Mol. Pharm. 4 2007 807 818
22. A.K. Ghosh et al. Curcumin inhibits prosurvival pathways in chronic lymphocytic leukemia B cells and may overcome their stromal protection in combination with EGCG Clin. Cancer Res. 15 2009 1250 1258
23. A. Goel et al. Curcumin as 'Curecumin': from kitchen to clinic Biochem. Pharmacol. 75 2008 787 809
24. M.T. Midura-Kiela et al. Curcumin inhibits interferon-gamma signaling in colonic epithelial cells Am. J. Physiol. Gastrointest. Liver Physiol. 302 2012 G85 G96
25. A. Hassaninasab et al. Discovery of the curcumin metabolic pathway involving a unique enzyme in an intestinal microorganism Proc. Natl. Acad. Sci. U.S.A. 108 2011 6615 6620
26. K. Sugimoto et al. Curcumin prevents and ameliorates trinitrobenzene sulfonic acid-induced colitis in mice Gastroenterology 123 2002 1912 1922
27. H. Hanai et al. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial Clin. Gastroenterol. Hepatol. 4 2006 1502 1506
28. R.E. Carroll et al. Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia Cancer Prev. Res. (Phila.) 4 2011 354 364
29. S.H. Rhee et al. Principles and clinical implications of the brain-gut-enteric microbiota axis Nat. Rev. Gastroenterol. Hepatol. 6 2009 306 314
30. P.Y. Wang et al. Upper intestinal lipids trigger a gut-brain-liver axis to regulate glucose production Nature 452 2008 1012 1016
31. J.F. Cryan, and T.G. Dinan Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour Nat. Rev. Neurosci. 13 2012 701 712
32. E. Holmes et al. Gut microbiota composition and activity in relation to host metabolic phenotype and disease risk Cell Metab. 16 2012 559 564
33. E. Holmes et al. Therapeutic modulation of microbiota-host metabolic interactions Sci. Transl. Med. 4 2012 137rv136
34. A.S. Attele et al. Ginseng pharmacology: multiple constituents and multiple actions Biochem. Pharmacol. 58 1999 1685 1693
35. Y. Chen et al. Wogonoside induces cell cycle arrest and differentiation by affecting expression and subcellular localization of PLSCR1 in AML cells Blood 121 2013 3682 3691
36. H. Hao et al. Identification of a novel intestinal first pass metabolic pathway: NQO1 mediated quinone reduction and subsequent glucuronidation Curr. Drug Metab. 8 2007 137 149
37. I.A. Qureshi, and M.F. Mehler Towards a 'systems'-level understanding of the nervous system and its disorders Trends Neurosci. 36 2013 674 684
38. M. Tsoli, and G. Robertson Cancer cachexia: malignant inflammation, tumorkines, and metabolic mayhem Trends Endocrinol. Metab. 24 2013 174 183
39. B. Jiang et al. Antidepressant-like effects of ginsenoside Rg1 are due to activation of the BDNF signalling pathway and neurogenesis in the hippocampus Br. J. Pharmacol. 166 2012 1872 1887
40. J. Zhu et al. Suppression of local inflammation contributes to the neuroprotective effect of ginsenoside Rb1 in rats with cerebral ischemia Neuroscience 202 2012 342 351
41. J. Wu et al. Ginsenoside Rg1 protection against β-amyloid peptide-induced neuronal apoptosis via estrogen receptor α and glucocorticoid receptor-dependent anti-protein nitration pathway Neuropharmacology 63 2012 349 361
42. K. Radad et al. Ginsenosides and their CNS targets CNS Neurosci. Ther. 17 2011 761 768
43. X. Zheng et al. Peripheral immunomodulation with ginsenoside Rg1 ameliorates neuroinflammation-induced behavioral deficits in rats Neuroscience 256C 2013 210 222
44. A. Kang et al. Peripheral anti-inflammatory effects explain the ginsenosides paradox between poor brain distribution and anti-depression efficacy J. Neuroinflammation 8 2011 100
45. H. Liu et al. Absorption and disposition of ginsenosides after oral administration of Panax notoginseng extract to rats Drug Metab. Dispos. 37 2009 2290 2298
46. D. Zwilling et al. Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration Cell 145 2011 863 874
47. J.R. Clapper et al. Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism Nat. Neurosci. 13 2010 1265 1270
48. P.H. Reinhart, and J.W. Kelly Treating the periphery to ameliorate neurodegenerative diseases Cell 145 2011 813 814
49. D.M. Lovinger Endocannabinoids rein in pain outside the brain Nat. Neurosci. 13 2010 1155 1156
50. C. Iadecola, and J. Anrather The immunology of stroke: from mechanisms to translation Nat. Med. 17 2011 796 808
51. V.W. Yong, and S. Rivest Taking advantage of the systemic immune system to cure brain diseases Neuron 64 2009 55 60
52. N. Marchi et al. Inflammatory pathways of seizure disorders Trends Neurosci. 37 2014 55 65
53. G.Y. Pan et al. The antihyperglycaemic activity of berberine arises from a decrease of glucose absorption Planta Med. 69 2003 632 636
54. W. Kong et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins Nat. Med. 10 2004 1344 1351
55. Y.T. Liu et al. Extensive intestinal first-pass elimination and predominant hepatic distribution of berberine explain its low plasma levels in rats Drug Metab. Dispos. 38 2010 1779 1784
56. X. Zhang et al. Structural changes of gut microbiota during berberine-mediated prevention of obesity and insulin resistance in high-fat diet-fed rats PLoS ONE 7 2012 e42529
57. J.K. Nicholson et al. Host-gut microbiota metabolic interactions Science 336 2012 1262 1267
58. D. Wang et al. Gut microbiota metabolism of anthocyanin promotes reverse cholesterol transport in mice via repressing miRNA-10b Circ. Res. 111 2012 967 981
59. X. Yin et al. Structural changes of gut microbiota in a rat non-alcoholic fatty liver disease model treated with a Chinese herbal formula Syst. Appl. Microbiol. 36 2013 188 196
60. M.F. Lu et al. Where do health benefits of flavonoids come from? Insights from flavonoid targets and their evolutionary history Biochem. Biophys. Res. Commun. 434 2013 701 704
61. X. Wang et al. Metabolic regulatory network alterations in response to acute cold stress and ginsenoside intervention J. Proteome Res. 6 2007 3449 3455
62. C. Liu et al. Increased glucagon-like peptide-1 secretion may be involved in antidiabetic effects of ginsenosides J. Endocrinol. 217 2013 185 196
63. S. Han et al. Effects of ginsenoside on pacemaker potentials of cultured interstitial cells of Cajal clusters from the small intestine of mice Mol. Cells 33 2012 243 249
64. M. Kosmala et al. Chemical composition of natural and polyphenol-free apple pomace and the effect of this dietary ingredient on intestinal fermentation and serum lipid parameters in rats J. Agric. Food Chem. 59 2011 9177 9185
65. X.L. Zhou et al. Soybean oligosaccharides alter colon short-chain fatty acid production and microbial population in vitro J. Anim. Sci. 90 Suppl. 4 2012 37 39
66. L.M. Cox, and M.J. Blaser Pathways in microbe-induced obesity Cell Metab. 17 2013 883 894
67. Z. Xu Modernization: one step at a time Nature 480 2011 S90 S92
68. X. Liu et al. Pharmacological tools for the development of traditional Chinese medicine Trends Pharmacol. Sci. 34 2013 620 628
69. W. Huang et al. A traditional herbal medicine enhances bilirubin clearance by activating the nuclear receptor CAR J. Clin. Invest. 113 2004 137 143
70. L. Wang et al. Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia Proc. Natl. Acad. Sci. U.S.A. 105 2008 4826 4831
71. X.W. Zhang et al. Arsenic trioxide controls the fate of the PML-RARα oncoprotein by directly binding PML Science 328 2010 240 243
72. T. Lu et al. Plasma and urinary tanshinol from Salvia miltiorrhiza (Danshen) can be used as pharmacokinetic markers for cardiotonic pills, a cardiovascular herbal medicine Drug Metab. Dispos. 36 2008 1578 1586
73. X. Qiu et al. Sulfotanshinone sodium injection for unstable angina pectoris: a systematic review of randomized controlled trials Evid. Based Complement. Alternat. Med. 2012 2012 http://dx.doi.org/10.1155/2012/715790
74. F. Sommer, and F. Backhed The gut microbiota - masters of host development and physiology Nat. Rev. Microbiol. 11 2013 227 238
75. J.J. Lu et al. Multi-target drugs: the trend of drug research and development PLoS ONE 7 2012 e40262
76. Z. Hu et al. Combinatorial metabolism notably affects human systemic exposure to ginsenosides from orally administered extract of Panax notoginseng roots (Sanqi) Drug Metab. Dispos. 41 2013 1457 1469
77. D.M. Jacobs et al. Non-digestible food ingredients, colonic microbiota and the impact on gut health and immunity: a role for metabolomics Curr. Drug Metab. 10 2009 41 54
78. S. Wang et al. Compatibility art of traditional Chinese medicine: from the perspective of herb pairs J. Ethnopharmacol. 143 2012 412 423
79. M. Xu et al. Pharmacokinetic comparisons of schizandrin after oral administration of schizandrin monomer, Fructus Schisandrae aqueous extract and Sheng-Mai-San to rats J. Ethnopharmacol. 115 2008 483 488
80. H.H. Zhu et al. Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial J. Clin. Oncol. 31 2013 4215 4221
81. H.P. Hao et al. Thoughts and experimental exploration on pharmacokinetic study of herbal medicines with multiple-components and targets Yao Xue Xue Bao 44 2009 270-275 (in Chinese)
82. C. Zheng et al. Diagnostic fragment-ion-based extension strategy for rapid screening and identification of serial components of homologous families contained in traditional Chinese medicine prescription using high-resolution LC-ESI-IT-TOF/MS: Shengmai injection as an example J. Mass Spectrom. 44 2009 230 244
83. H. Hao et al. Global detection and identification of nontarget components from herbal preparations by liquid chromatography hybrid ion trap time-of-flight mass spectrometry and a strategy Anal. Chem. 80 2008 8187 8194
84. L. Wu et al. An integral strategy toward the rapid identification of analogous nontarget compounds from complex mixtures J. Chromatogr. A 1303 2013 39 47
85. P. Gong et al. Chemicalome and metabolome matching approach to elucidating biological metabolic networks of complex mixtures Anal. Chem. 84 2012 2995 3002
86. M. Rask-Andersen et al. Trends in the exploitation of novel drug targets Nat. Rev. Drug Discov. 10 2011 579 590